Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability (2014 - 2015)
Alnylam Pharmaceuticals posted quarterly Curent Deferred Tax Liability of $9.4 million for Q3 2015, down 52.14% on a QoQ basis from $19.7 million in Q2 2015.
Alnylam Pharmaceuticals (ALNY) has 2 years of Curent Deferred Tax Liability data on file, last reported at $9.4 million in Q3 2015.
- For the quarter ending Q3 2015, Curent Deferred Tax Liability changed N/A year-over-year to $9.4 million; the trailing twelve-month figure through Sep 2015 stood at $9.4 million (changed N/A YoY), and the FY2014 full-year result was $31.7 million, changed N/A from the prior year.
- Curent Deferred Tax Liability for Q3 2015 stood at $9.4 million, down from $19.7 million in the prior quarter.
- Across five years, Curent Deferred Tax Liability topped out at $33.7 million in Q1 2015 and bottomed at $9.4 million in Q3 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 9.41 Mn |
| Sep 30, 2015 | 9.41 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 31.67 Mn |
| Dec 31, 2014 | 31.67 Mn |